![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
X
20
S.a.l.a.r.s. S.p.a. Como It, based in U.S.A, is a pharmaceutical company.
One of their significant offerings is Naltrexone hydrochloride, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2006-117 - Rev 02
This Chemical Type CEP, issued on May 05, 2017, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1790 associated with this CEP further emphasizes